Skip to content

Study · Animal study (in vivo) · rat · 2023

9 results

Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury.

Sarode LP, Ghatage T, Mardhekar V, Verma B, Prakash A, Ugale RR

Metabolic brain disease5 Jun 2023Cited by 12 (Europe PMC)

PMID37273080 (opens in a new tab)DOI10.1007/s11011-023-01240-4 (opens in a new tab)PepBankPUB-37273080
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after ischemic reperfusion, Cerebrolysin reduced neuronal cell death versus vehicle.

    In plain wordsIn rats after ischemic reperfusion, Cerebrolysin reduced nerve cell death compared with vehicle.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeuronal cell death
    Study

    ratn: not reported in source

    ischemic reperfusion injury
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.15 or 0.30 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Our in-vivo and in-vitro findings showed that cerebrolysin substantially reduced neuronal cell death in delayed hours of post ischemic- and glutamate-insult conditions respectively.
    1 context sentence
    Summary · context
    Adult male Wistar rats were intraperitoneally treated with cerebrolysin (0.15 or 0.30 mg/kg) or vehicle at 3, 6 and 12 h after ischemic reperfusion and were assessed 24 h after reperfusion in ischemic rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats after ischemic reperfusion, Cerebrolysin reduced SREBP1 expression.

    In plain wordsIn rats after ischemic reperfusion, Cerebrolysin reduced SREBP1 expression.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSREBP1 expression
    Study

    ratn: not reported in source

    ischemic reperfusion injury
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.15 or 0.30 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Importantly, we also found that cerebrolysin reduced SREBP1 expression, which gets activated only after 6 h of ischemia.
    1 context sentence
    Summary · context
    Adult male Wistar rats were intraperitoneally treated with cerebrolysin (0.15 or 0.30 mg/kg) or vehicle at 3, 6 and 12 h after ischemic reperfusion and were assessed 24 h after reperfusion in ischemic rats.
  3. 03AnimalOther designMechanism

    In experimental ischemic and glutamate injury models, Cerebrolysin restrained extrasynaptic NR2B upregulation.

    In plain wordsIn experimental injury models, Cerebrolysin reduced extrasynaptic NR2B upregulation.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseExtrasynaptic NR2B upregulation
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that cerebrolysin restrained upregulation of extrasynaptic NR2B responsible for triggering apoptotic pathways.
  4. 04AnimalOther designMechanism

    In experimental injury models, Cerebrolysin reduced JNK expression.

    In plain wordsIn experimental injury models, Cerebrolysin reduced JNK expression.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseJNK expression
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cerebrolysin reduced expression of important cell death proteins such as, JNK, PTEN, Calpain and Caspase-3 components.
  5. 05AnimalOther designMechanism

    In experimental injury models, Cerebrolysin reduced PTEN expression.

    In plain wordsIn experimental injury models, Cerebrolysin reduced PTEN expression.

    Peptide
    Cerebrolysin
    Outcome
    DecreasePTEN expression
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cerebrolysin reduced expression of important cell death proteins such as, JNK, PTEN, Calpain and Caspase-3 components.
  6. 06AnimalOther designMechanism

    In experimental injury models, Cerebrolysin reduced Calpain expression.

    In plain wordsIn experimental injury models, Cerebrolysin reduced Calpain expression.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCalpain expression
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cerebrolysin reduced expression of important cell death proteins such as, JNK, PTEN, Calpain and Caspase-3 components.
  7. 07AnimalOther designMechanism

    In experimental injury models, Cerebrolysin reduced Caspase-3 expression.

    In plain wordsIn experimental injury models, Cerebrolysin reduced Caspase-3 expression.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCaspase-3 expression
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cerebrolysin reduced expression of important cell death proteins such as, JNK, PTEN, Calpain and Caspase-3 components.
  8. 08LabIn vitro (cells)Efficacy outcome

    In cortical cell cultures after glutamate exposure, Cerebrolysin reduced neuronal cell death versus vehicle.

    In plain wordsIn cells after glutamate exposure, Cerebrolysin reduced nerve cell death compared with vehicle.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeuronal cell death
    Study

    n: not reported in source

    primary cortical culture cells after glutamate exposure
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 or 5 mg/mlAs given in this study.

    Source sentences

    Summary
    Our in-vivo and in-vitro findings showed that cerebrolysin substantially reduced neuronal cell death in delayed hours of post ischemic- and glutamate-insult conditions respectively.
    1 context sentence
    Summary · context
    We added cerebrolysin (2.5 or 5 mg/ml) or vehicle in primary cortical culture cells at 3, 6 and 12 h of post-glutamate exposure and performed cell viability assays at 24 h.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 09AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Mechanism

    In rats, RO25-6981 pretreatment enhanced Cerebrolysin neuroprotection at 6 h of reperfusion.

    In plain wordsIn rats, RO25-6981 pretreatment enhanced Cerebrolysin neuroprotection during reperfusion.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeuroprotection with NR2B antagonism
    Study

    ratn: not reported in source

    ischemic reperfusion injury
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Neuroprotective effect of cerebrolysin at 6 h of reperfusion was enhanced by pretreatment of NR2B antagonist RO25-6981.
    1 context sentence
    Summary · context
    Further, we have assessed the influence of NR-2 A/-2B receptor antagonism on neuroprotective action of cerebrolysin at 6 h in in-vivo as well as in-vitro conditions.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.